Research Trends
|
Advancements in CAR-T Cell Therapy: Maximizing Therapeutic Efficacy while Minimizing Toxicity |
May 26, 2023 |
In the last chapter (click to review), we mentioned that chimeric antigen receptor (CAR)-T cell therapy has been extremely successful in treating relapsed/refractory B-cell malignancies expressing CD19, however, there are still many toxicities in clinical applications, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Read More > |
Research Trends
|
What are the obstacles hindering the development of CAR-T therapy? |
May 18, 2023 |
After years of development, chimeric antigen receptor (CAR) T cell therapy has become a revolutionary method for cancer treatment. Among them, CD19 targeting drugs have achieved unprecedented success in the treatment of B-cell malignancies and were approved by the US FDA in 2017. Read More > |
Research Trends
|
Mastering CAR Structure and Design for Enhanced Anti-Tumor Response with CAR-T Cell Therapy |
May 12, 2023 |
Chimeric antigen receptors (CARs) are engineered synthetic receptors that redirect lymphocytes, most commonly T-cells, to recognize and eliminate cells expressing specific target antigens. CAR binding to target antigens on the cell surface is independent of MHC receptors, resulting in vigorous T-cell activation and potent anti-tumor responses. Read More > |
Research Trends
|
Frequently Asked Questions (FAQ) on Mouse Models for Ophthalmic Diseases |
Apr 21, 2023 |
Due to the limited efficacy of traditional treatments, ophthalmic diseases have quickly become a breakthrough point for gene therapy, but many questions about mouse models for preclinical ophthalmology research remain. Read More > |
Research Trends
|
Revolutionizing Neovascular Ophthalmology Research: Cyagen's Phenotypically Stable Humanized VEGF Mice |
Apr 13, 2023 |
As a popular target for treating diseases like macular degeneration and tumors, vascular endothelial growth factor (VEGF) has already had several drugs approved for clinical use and has made significant progress. In February of this year, researchers completed the first Phase I clinical trial of a recombinant anti-VEGFA and VEGFC bispecific antibody fusion protein in a for age-related macular degeneration with neovascularization. Read More > |
Research Trends
|
Humanized VEGFA Mouse Models for Preclinical Wet AMD Ophthalmology Research |
Mar 30, 2023 |
Recently, researchers announced that they have found a new target for inhibiting vascular endothelial growth factor (VEGF), which can improve the symptoms of ophthalmic diseases. This is achieved by affecting the release of VEGF and choroidal neovascularization through fat mass and obesity-associated protein (FTO) inhibition. Read More > |
Research Trends
|
Applications of iPSC-based Disease Models |
Feb 16, 2023 |
Induced pluripotent stem cells (iPSCs) provide an ideal in vitro platform for studying disease mechanisms and developing cell therapy approaches, as they can be derived from cells with a singular genetic background and tailored to replicate specific disease phenotypes. Read More > |
Research Trends
|
What is Autism Spectrum Disorder (ASD) and what are the gene-edited mouse models for autism? |
Jan 29, 2023 |
Autism Spectrum Disorder (ASD) refers to a broad range of complex neurodevelopmental conditions that has many theorized causative factors, but there have been many genetic mutations associated with susceptibility to autism and altered brain structure associated with ASD. Read More > |
Research Trends
|
How Much Do You Know About The Behavioral Differences Between Rats And Mice? |
Jan 16, 2023 |
Murine genomes share great similarity with the human genome, which has made both mice and rats fantastic models for a wide range human disease research. Read More > |
Research Trends
|
The Morris Water Maze: Illustrated Handbook for Researchers |
Jan 10, 2023 |
The Morris water maze is a widely used task in behavioral neuroscience for the study of spatial learning and memory, while additionally testing endurance and physical strength. Read More > |